Physician profile
Michael Kaplan
NPI 1073925913
$8,885.28
in general payments reported to CMS, 2019-2025
10 companies · $6,520 in 2025
The $6,520 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $105 · 2022: $129 · 2023: $22.79 · 2024: $2,109 · 2025: $6,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,668 · Food and Beverage: $1,410 · Travel and Lodging: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,668.00 |
| Food and Beverage | $1,410.10 |
| Travel and Lodging | $573.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $6,292.55 | 2025 | Tonmya, Zembrace Symtouch |
| Janssen Biotech, INC. | $1,861.88 | 2024 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $253.61 | 2022-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $113.62 | 2023-2024 | Benlysta |
| Encore Medical, Lp | $104.99 | 2020 | |
| Sobi, INC | $96.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $76.50 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $54.18 | 2025 | |
| Genentech USA, INC. | $17.12 | 2024 | Actemra |
| Pfizer INC. | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.